Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study

REFERENCES

1. 1.↵
   1. Smolen JS,
   2. Aletaha D,
   3. Bijlsma JW,
   4. Breedveld FC,
   5. Boumpas D,
   6. Burmester G,
   7. et al;
   8. T2T Expert Committee

   . Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Porter D,
   2. Dale J,
   3. Sattar N

   . How low to aim in rheumatoid arthritis? Learning from other disciplines. Ann Rheum Dis 2014;73:480–2.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Atar D,
   2. Birkeland KI,
   3. Uhlig T

   . ‘Treat to target’: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann Rheum Dis 2010;69:629–30.

   OpenUrlFREE Full Text
4. 4.↵
   1. van Tuyl LH,
   2. Felson DT,
   3. Wells G,
   4. Smolen J,
   5. Zhang B,
   6. Boers M;
   7. American College of Rheumatology;
   8. European League against Rheumatism Committee to Define Remission for Clinical Trials

   . Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res 2010;62:108–17.

   OpenUrlCrossRef
5. 5.↵
   1. Radner H,
   2. Smolen JS,
   3. Aletaha D

   . Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 2014;16:R56.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Felson DT,
   2. Smolen JS,
   3. Wells G,
   4. Zhang B,
   5. van Tuyl LH,
   6. Funovits J,
   7. et al.

   American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Prevoo ML,
   2. van ‘t Hof MA,
   3. Kuper HH,
   4. van Leeuwen MA,
   5. van de Putte LB,
   6. van Riel PL

   . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Aletaha D,
   2. Smolen JS

   . The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:663–75.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Pincus T,
   2. Bergman MJ,
   3. Yazici Y,
   4. Hines P,
   5. Raghupathi K,
   6. Maclean R

   . An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology 2008;47:345–9.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Kvien TK,
    2. Heiberg,
    3. Lie E,
    4. Kaufmann C,
    5. Mikkelsen K,
    6. Nordvag BY,
    7. et al.

    A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23 Suppl 39:S188–94.

    OpenUrlPubMed
11. 11.↵
    1. Uhlig T,
    2. Kvien TK,
    3. Pincus T

    . Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009;68:972–5.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Yazici Y,
    2. Simsek I

    . Tools for monitoring remission in rheumatoid arthritis: any will do, let’s just pick one and start measuring. Arthritis Res Ther 2013;15:104.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Thiele K,
    2. Huscher D,
    3. Bischoff S,
    4. Späthling-Mestekemper S,
    5. Backhaus M,
    6. Aringer M,
    7. et al.

    Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:1194–9.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Khanna D,
    2. Oh M,
    3. Furst DE,
    4. Ranganath V,
    5. Gold RH,
    6. Sharp JT,
    7. et al;
    8. Western Consortium of Practicing Rheumatologists

    . Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007;57:440–7.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Kuriya B,
    2. Sun Y,
    3. Boire G,
    4. Haraoui B,
    5. Hitchon C,
    6. Pope JE,
    7. et al;
    8. Canadian Early Arthritis Cohort Study

    . Remission in early rheumatoid arthritis — a comparison of new ACR/EULAR remission criteria to established criteria. J Rheumatol 2012;39:1155–8.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Shahouri SH,
    2. Michaud K,
    3. Mikuls TR,
    4. Caplan L,
    5. Shaver TS,
    6. Anderson JD,
    7. et al.

    Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011;63:3204–15.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Shaver TS,
    2. Anderson JD,
    3. Weidensaul DN,
    4. Shahouri SH,
    5. Busch RE,
    6. Mikuls TR,
    7. et al.

    The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35:1015–22.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Mierau M,
    2. Schoels M,
    3. Gonda G,
    4. Fuchs J,
    5. Aletaha D,
    6. Smolen JS

    . Assessing remission in clinical practice. Rheumatology 2007;46:975–9.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Sakellariou G,
    2. Scirè CA,
    3. Verstappen SM,
    4. Montecucco C,
    5. Caporali R

    . In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 2013;72:245–9.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Bosello S,
    2. Fedele AL,
    3. Peluso G,
    4. Gremese E,
    5. Tolusso B,
    6. Ferraccioli G

    . Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 2011;70:1292–5.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Furst DE,
    2. Pangan AL,
    3. Harrold LR,
    4. Chang H,
    5. Reed G,
    6. Kremer JM,
    7. et al.

    Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res 2011;63:856–64.

    OpenUrlCrossRef
22. 22.↵
    1. Smolen JS,
    2. Landewé R,
    3. Breedveld FC,
    4. Buch M,
    5. Burmester G,
    6. Dougados M,
    7. et al.

    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Aga AB,
    2. Lie E,
    3. Uhlig T,
    4. Olsen IC,
    5. Wierød A,
    6. Kalstad S,
    7. et al.

    Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis 2015;74:381–8.

    OpenUrlAbstract/FREE Full Text